PetVivo Holdings, Inc. (OTCQX: PETV; OTC ID: PETVW), through its wholly owned subsidiary Petvivo Animal Health, a leading biomedical company delivering innovative medical devices and therapeutics for ...

Cost of revenues for the nine months ended September 30, 2025 totaled $7.9 million compared to $11.4 million in the same period last year. The decrease was primarily due to a decrease in jet card and ...

In both fatal cases, patients developed markedly elevated liver enzymes and required hospitalization within two months of Elevidys infusion. An additional serious, non-fatal case of acute liver injury ...

Leading CIOs honored for leadership, innovation, and business impact. NEW YORK, Nov. 14, 2025 (GLOBE NEWSWIRE) -- The 2025 ...

America’s Top Financial Advisory Firms award received in 2026 were granted by Newsweek, with assistance from Plant-A Insights Group. McAdam LLC did not apply for or pay for the award. The ranking of ...

The Oslo, Stadt-Bond has a maturity date of 10/23/2035 and offers a coupon of 4.3700%. The payment of the coupon will take place 1,0 times per Year on the 23.10.. At the current price of 100.813 NOK ...

DARE to PLAY™ Sildenafil Cream on Track to Launch Before Year End via 503B Pathway, Paving the Way for Near-Term Product Revenue Positive Interim ...

Investors probably aren't getting the economic data they've been missing, even with the shutdown ending. Rate-cut views for ...

Copyright © 2025 Insider Inc and finanzen.net GmbH (Imprint). All rights reserved. Registration on or use of this site constitutes acceptance of our Terms of Service ...

CERRITOS, Calif., Nov. 13, 2025 (GLOBE NEWSWIRE) -- The Oncology Institute, Inc. (NASDAQ: TOI) (“TOI” or the “Company”), one of the largest value-based community oncology groups in the United States, ...

Presented new data at the Society of Immunotherapy for Cancer (SITC) annual meeting on CLD-401 protection from immune clearance after systemic ...

Alumis Inc. (Nasdaq: ALMS), a clinical-stage biopharmaceutical company developing next-generation targeted therapies for patients with immune-mediated diseases, today reported financial results for ...